Table 5.
ANOVA-derived maximum observed R-(+)-ALA enantiomer geometric LS mean plasma concentrations (Cmax) and the corresponding 95% CI by sex (12 males/12 females) and treatment
| R-(+) Cmax LS means and CI Male subjects (N=12)
|
R-(+) Cmax LS means and CI Female subjects (N=12)
|
|||||
|---|---|---|---|---|---|---|
| Treatment | Geometric mean (ng · mL−1) | 95% CI
|
Geometric mean (ng · mL−1) | 95% CI
|
||
| Lower | Upper | Lower | Upper | |||
| OS | 7,413.7 | 5,280.4 | 10,409.0 | 8,298.8 | 6,880.4 | 10,009.5 |
| T 200 | 3,036.8 | 1,953.6 | 4,720.6 | 3,751.1 | 2,725.1 | 5,163.5 |
| T 300 | 3,574.4 | 2,350.9 | 5,434.7 | 3,609.5 | 2,351.0 | 5,541.7 |
| T 600 | 2,389.2 | 1,586.6 | 3,598.0 | 3,334.4 | 2,547.4 | 4,364.6 |
Abbreviations: ANOVA, analysis of variance; ALA, alpha-lipoic acid; LS, least squares; Cmax, maximum observed plasma concentration; CI, confidence interval; N, number; OS, orally administered ALA solution; T 200, 200 mg tablet; T 300, 300 mg tablet; T 600, 600 mg tablet.